| MEN1 Deficiency-Driven Activation of the beta-Catenin-MGMT Axis Promotes Pancreatic Neuroendocrine Tumor Growth and Confers Temozolomide Resistance. | MEN1 Deficiency-Driven Activation of the β-Catenin-MGMT Axis Promotes Pancreatic Neuroendocrine Tumor Growth and Confers Temozolomide Resistance.
Xu J, Lou X, Wang F, Zhang W, Xu X, Ye Z, Zhuo Q, Wang Y, Jing D, Fan G, Chen X, Zhang Y, Zhou C, Chen J, Qin Y, Yu X, Ji S., Free PMC Article | 10/1/2024 |
| Adaptive fine-tuning based transfer learning for the identification of MGMT promoter methylation status. | Adaptive fine-tuning based transfer learning for the identification of MGMT promoter methylation status.
Schmitz E, Guo Y, Wang J., Free PMC Article | 09/9/2024 |
| The interplay mechanism between IDH mutation, MGMT-promoter methylation, and PRMT5 activity in the progression of grade 4 astrocytoma: unraveling the complex triad theory. | The interplay mechanism between IDH mutation, MGMT-promoter methylation, and PRMT5 activity in the progression of grade 4 astrocytoma: unraveling the complex triad theory.
Kurdi M, Alkhotani A, Sabbagh A, Faizo E, Lary AI, Bamaga AK, Almansouri M, Hafiz B, Alsharif T, Baeesa S., Free PMC Article | 08/30/2024 |
| O[6] -methylguanine methyltransferase promoter methylation status of glioblastoma cell line clonal population. | O(6) -methylguanine methyltransferase promoter methylation status of glioblastoma cell line clonal population.
Anan M, Del Maestro RF, Hata N, Fujiki M. | 07/2/2024 |
| Predominance of MGMT promoter methylation among Pakistani glioblastoma patients. | Predominance of MGMT promoter methylation among Pakistani glioblastoma patients.
Muhammad N, Fasih S, Malik B, Hameed S, Loya A, Rashid MU. | 04/17/2024 |
| Constitutional BRCA1 and MGMT Methylation Are Significant Risk Factors for Triple-Negative Breast Cancer and High-Grade Serous Ovarian Cancer in Saudi Women. | Constitutional BRCA1 and MGMT Methylation Are Significant Risk Factors for Triple-Negative Breast Cancer and High-Grade Serous Ovarian Cancer in Saudi Women.
Al-Moghrabi N, Al-Showimi M, Alqahtani A, Almalik O, Alhusaini H, Almalki G, Saad A, Alsunayi E., Free PMC Article | 04/2/2024 |
| Proteomic and metabolomic analyses illustrate the mechanisms of expression of the O[6] -methylguanine-DNA methyltransferase gene in glioblastoma. | Proteomic and metabolomic analyses illustrate the mechanisms of expression of the O(6) -methylguanine-DNA methyltransferase gene in glioblastoma.
Chen X, Sun J, Li Y, Jiang W, Li Z, Mao J, Zhou L, Chen S, Tan G., Free PMC Article | 03/4/2024 |
| Glioblastoma with high O6-methyl-guanine DNA methyltransferase expression are more immunologically active than tumors with low MGMT expression. | Glioblastoma with high O6-methyl-guanine DNA methyltransferase expression are more immunologically active than tumors with low MGMT expression.
Kushihara Y, Tanaka S, Kobayashi Y, Nagaoka K, Kikuchi M, Nejo T, Yamazawa E, Nambu S, Kugasawa K, Takami H, Takayanagi S, Saito N, Kakimi K., Free PMC Article | 03/1/2024 |
| Circadian regulation of MGMT expression and promoter methylation underlies daily rhythms in TMZ sensitivity in glioblastoma. | Circadian regulation of MGMT expression and promoter methylation underlies daily rhythms in TMZ sensitivity in glioblastoma.
Gonzalez-Aponte MF, Damato AR, Trebucq LL, Simon T, Cárdenas-García SP, Cho K, Patti GJ, Golombek DA, Chiesa JJ, Rubin JB, Herzog ED., Free PMC Article | 02/21/2024 |
| Pyrosequencing Analysis of O-6-Methylguanine-DNA Methyltransferase Methylation at Different Cut-Offs of Positivity Associated with Treatment Response and Disease-Specific Survival in Isocitrate Dehydrogenase-Wildtype Grade 4 Glioblastoma. | Pyrosequencing Analysis of O-6-Methylguanine-DNA Methyltransferase Methylation at Different Cut-Offs of Positivity Associated with Treatment Response and Disease-Specific Survival in Isocitrate Dehydrogenase-Wildtype Grade 4 Glioblastoma.
Silva FFVE, Di Domenico M, Caponio VCA, Pérez-Sayáns M, Camolesi GCV, Rojo-Álvarez LI, Ballini A, García-García A, Padín-Iruegas ME, Suaréz-Peñaranda JM., Free PMC Article | 01/16/2024 |
| IDH1-mutated Crohn's disease-associated small bowel adenocarcinomas: Distinctive pathological features and association with MGMT methylation and serrated-type dysplasia. | IDH1-mutated Crohn's disease-associated small bowel adenocarcinomas: Distinctive pathological features and association with MGMT methylation and serrated-type dysplasia.
Guerini C, Furlan D, Ferrario G, Grillo F, Libera L, Arpa G, Klersy C, Lenti MV, Riboni R, Solcia E, Fassan M, Mastracci L, Ardizzone S, Moens A, De Hertogh G, Ferrante M, Graham RP, Sessa F, Paulli M, Di Sabatino A, Vanoli A. | 01/15/2024 |
| Cognitive functioning is prognostic in patients with IDH1-wild type and MGMT-unmethylated high-grade gliomas. | Cognitive functioning is prognostic in patients with IDH1-wild type and MGMT-unmethylated high-grade gliomas.
Smrdel U, Škufca Smrdel AC, Podlesek A, Skoblar Vidmar M, Kos G, Markovic J, Jereb J, Knific J, Rus T., Free PMC Article | 01/9/2024 |
| Mass Spectrometric Analysis of the Active Site Tryptic Peptide of Recombinant O[6]-Methylguanine-DNA Methyltransferase Following Incubation with Human Colorectal DNA Reveals the Presence of an O[6]-Alkylguanine Adductome. | Mass Spectrometric Analysis of the Active Site Tryptic Peptide of Recombinant O(6)-Methylguanine-DNA Methyltransferase Following Incubation with Human Colorectal DNA Reveals the Presence of an O(6)-Alkylguanine Adductome.
Abdelhady R, Senthong P, Eyers CE, Reamtong O, Cowley E, Cannizzaro L, Stimpson J, Cain K, Wilkinson OJ, Williams NH, Barran PE, Margison GP, Williams DM, Povey AC., Free PMC Article | 12/27/2023 |
| Preferential MGMT hypermethylation in SDH-deficient wild-type GIST. | Preferential MGMT hypermethylation in SDH-deficient wild-type GIST.
Giger OT, Ten Hoopen R, Shorthouse D, Abdullahi S, Bulusu VR, Jadhav S, Maher ER, Casey RT., Free PMC Article | 12/18/2023 |
| Total DNA methylation profile in assessing the MGMT gene promoter status in malignant gliomas. | Total DNA methylation profile in assessing the MGMT gene promoter status in malignant gliomas.
Petrova EI, Galstyan SA, Telysheva EN, Ryzhova MV. | 12/15/2023 |
| ABERRANT METHYLATION OF CANCER-RELATED GENES IN VIETNAMESE BREAST CANCER PATIENTS: ASSOCIATIONS WITH CLINICOPATHOLOGICAL FEATURES. | ABERRANT METHYLATION OF CANCER-RELATED GENES IN VIETNAMESE BREAST CANCER PATIENTS: ASSOCIATIONS WITH CLINICOPATHOLOGICAL FEATURES.
Dieu Vuong L, Ngoc Nguyen Q. | 12/6/2023 |
| DDX5 (p68) orchestrates beta-catenin, RelA and SP1 mediated MGMT gene expression in human colon cancer cells: Implication in TMZ chemoresistance. | DDX5 (p68) orchestrates β-catenin, RelA and SP1 mediated MGMT gene expression in human colon cancer cells: Implication in TMZ chemoresistance.
Shaw R, Karmakar S, Basu M, Ghosh MK. | 11/20/2023 |
| Variant allelic frequencies of driver mutations can identify gliomas with potentially false-negative MGMT promoter methylation results. | Variant allelic frequencies of driver mutations can identify gliomas with potentially false-negative MGMT promoter methylation results.
McCord M, Jamshidi P, Thirunavu V, Santana-Santos L, Vormittag-Nocito E, Dittman D, Parker S, Baczkowski J, Jennings L, Walshon J, McCortney K, Galbraith K, Zhang H, Lukas RV, Stupp R, Dixit K, Kumthekar P, Heimberger AB, Snuderl M, Horbinski C., Free PMC Article | 11/8/2023 |
| Genetic and epigenetic alterations in MGMT gene and correlation with concomitant chemoradiotherapy (CRT) in cervical cancer. | Genetic and epigenetic alterations in MGMT gene and correlation with concomitant chemoradiotherapy (CRT) in cervical cancer.
Gupta MK, Kushwah AS, Singh R, Srivastava K, Banerjee M. | 10/30/2023 |
| Association of MGMT Promoter Methylation With Survival in Low-grade and Anaplastic Gliomas After Alkylating Chemotherapy. | Association of MGMT Promoter Methylation With Survival in Low-grade and Anaplastic Gliomas After Alkylating Chemotherapy.
Kinslow CJ, Mercurio A, Kumar P, Rae AI, Siegelin MD, Grinband J, Taparra K, Upadhyayula PS, McKhann GM, Sisti MB, Bruce JN, Canoll PD, Iwamoto FM, Kachnic LA, Yu JB, Cheng SK, Wang TJC., Free PMC Article | 09/11/2023 |
| Significance of O6-methyl guanine methyltransferase promoter methylation in high grade glioma patients: optimal cutoff point, CpG locus, and genetic assay. | Significance of O6-methyl guanine methyltransferase promoter methylation in high grade glioma patients: optimal cutoff point, CpG locus, and genetic assay.
Buyuktepe M, Kaplan I, Bayatli E, Dogan H, Ugur HC. | 08/30/2023 |
| ERCC1 and MGMT Methylation as a Predictive Marker of Relapse and FOLFOX Response in Colorectal Cancer Patients from South Tunisia. | ERCC1 and MGMT Methylation as a Predictive Marker of Relapse and FOLFOX Response in Colorectal Cancer Patients from South Tunisia.
Jamai D, Gargouri R, Selmi B, Khabir A., Free PMC Article | 08/9/2023 |
| Treatment benefit in patients aged 80 years or older with biopsy-proven and non-resected glioblastoma is dependent on MGMT promoter methylation status. | Treatment benefit in patients aged 80 years or older with biopsy-proven and non-resected glioblastoma is dependent on MGMT promoter methylation status.
Weller J, Katzendobler S, Niedermeyer S, Harter PN, Herms J, Trumm C, Niyazi M, Thon N, Tonn JC, Stoecklein VM., Free PMC Article | 07/10/2023 |
| Downregulation of BASP1 Promotes Temozolomide Resistance in Gliomas via Epigenetic Activation of the FBXO32/NF-kappaB/MGMT Axis. | Downregulation of BASP1 Promotes Temozolomide Resistance in Gliomas via Epigenetic Activation of the FBXO32/NF-κB/MGMT Axis.
Liao X, Li Z, Zheng H, Qian W, Zhang S, Chen S, Li X, Tang M, Xu Y, Yu R, Li M, Song L, Li J. | 07/7/2023 |
| Association between MGMT Enhancer Methylation and MGMT Promoter Methylation, MGMT Protein Expression, and Overall Survival in Glioblastoma. | Association between MGMT Enhancer Methylation and MGMT Promoter Methylation, MGMT Protein Expression, and Overall Survival in Glioblastoma.
Zappe K, Pühringer K, Pflug S, Berger D, Böhm A, Spiegl-Kreinecker S, Cichna-Markl M., Free PMC Article | 07/5/2023 |